Filgrastim (Nivestim®)

All Wales Medicines Strategy Group (AWMSG)
Record ID 32012000365
English
Authors' recommendations: Filgrastim (Nivestim®) is recommended as an option for use within NHS Wales for the treatment of neutropenia: - For the reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes) and for the reduction in the duration of neutropenia in patients undergoing myeloablative therapy followed by bone marrow transplantation considered to be at increased risk of prolonged severe neutropenia. The safety and efficacy of filgrastim are similar in adults and children receiving cytotoxic chemotherapy. - For the mobilisation of peripheral blood progenitor cells (PBPC). - In patients, children or adults, with severe congenital, cyclic, or idiopathic neutropenia with an absolute neutrophil count (ANC) of 0.5 × 109/l and a history of severe or recurrent infections, long term administration of (Nivestim®) is indicated to increase neutrophil counts and to reduce the incidence and duration of infection-related events. - For the treatment of persistent neutropenia (ANC less than or equal to 0.5 × 109/l) in patients with advanced HIV infection, in order to reduce the risk of bacterial infections when other options to manage neutropenia are inappropriate. - Filgrastim (Nivestim®) is not suitable for shared care within NHS Wales for the above indication. - Filgrastim (Nivestim®) should be prescribed by brand name to avoid automatic substitution and therefore help with pharmacovigilance.
Details
Project Status: Completed
Year Published: 2011
URL for published report: http://www.wales.nhs.uk/sites3/docmetadata.cfm?orgid=371&id=170529&pid=24773
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Wales, United Kingdom
MeSH Terms
  • Humans
  • Neutropenia
  • Recombinant Proteins
  • Granulocyte Colony-Stimulating Factor
Contact
Organisation Name: All Wales Medicines Strategy Group
Contact Address: All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Contact Name: AWTTC@wales.nhs.uk
Contact Email: AWTTC@wales.nhs.uk
Copyright: AWTTC
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.